PEEKplus®
FDA Cleared
First FDA Cleared Nanotechnology PEEK
Devices for Spinal Intervertebral Fusion
FDA Cleared
First FDA Cleared Nanotechnology PEEK
Devices for Spinal Intervertebral Fusion
Vallum’s in vitro and in vivo studies have shown its subtractive nanotexturing on PEEK significantly increases osseointegration as compared to control PEEK. Vallum’s in vitro studies have also shown its subtractive nanotexturing on PEEK significantly reduced bacterial attachment as compared to control PEEK. The in vitro study results correlated with significantly increased adsorption of beneficial proteins on nanotextured PEEK as compared to control PEEK. Adsorption is the adhesion of molecules from a liquid to a surface. This process creates a film of the adsorbate on the surface of the adsorbent. This process differs from absorption, in which a fluid permeates a solid.
ANAB processing on PEEKplus creates a subtractive nanotexturing that removes less than 50 nanometers of material from the surface of the PEEK. Since PEEKplus interbody cages are millions of nanometers thick, this imperceptible topographical change has no effect on dimensions, no effect on mechanical strength, no effect on design and no effect on chemical composition. ANAB nanotexturing fully preserves all of PEEKplus’ positive attributes.
Vallum has not conducted any clinical studies to support its in vitro and in vivo results and they are not presented as claims of clinical efficacy.
The ANAB subtractive nanotexturing on PEEKplus can be applied to any company’s current line of PEEK devices in one final, quick, and inexpensive production step prior to sterilization.
Any company’s current surgeon customers can seamlessly transition to a PEEK interbody device with ANAB subtractive nanotexturing without the need for retraining or new instrumentation – exact same technique, exact same implant, but now ANAB nanotextured.
ANAB subtractive nanotexturing is proprietary and differentiable in an otherwise crowded spine interbody device market.